1. Home
  2. PRPO vs ATOS Comparison

PRPO vs ATOS Comparison

Compare PRPO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$30.50

Market Cap

44.4M

Sector

Industrials

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$5.90

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPO
ATOS
Founded
N/A
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
36.2M
IPO Year
2000
2010

Fundamental Metrics

Financial Performance
Metric
PRPO
ATOS
Price
$30.50
$5.90
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
14.9K
48.0K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
92.15
N/A
EPS
N/A
N/A
Revenue
$24,049,000.00
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.77
N/A
52 Week Low
$5.94
$0.53
52 Week High
$32.40
$7.56

Technical Indicators

Market Signals
Indicator
PRPO
ATOS
Relative Strength Index (RSI) 55.33 60.72
Support Level $22.96 $0.66
Resistance Level N/A $6.19
Average True Range (ATR) 1.71 0.36
MACD 0.15 -0.04
Stochastic Oscillator 61.12 72.27

Price Performance

Historical Comparison
PRPO
ATOS

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: